prodchem
Aug 27, 2026
Global pharmaceutical manufacturing output jumped 9.1% in 2025, but the headline growth rate tells only half the story. Industry analysis attributes much of the surge to manufacturers accelerating production and building inventory ahead of anticipated US tariff measures.
That creates an unusual setup for 2026.
Instead of treating the 2025 increase as a new demand baseline, pharmaceutical manufacturers, API suppliers and chemical traders need to consider what happens when those accumulated inventories move through distribution channels. Atradius expects global pharmaceutical production growth to slow to 1.6% in 2026 as the sector retrenches after the front-loaded production surge.
For procurement teams, the risk is a demand cliff: orders can weaken even while end-market medicine demand remains relatively stable.
The 2025 production increase was unusually strong because manufacturers had a powerful reason to produce earlier than normal.
Companies anticipating US tariff actions brought forward manufacturing and inventory decisions. That allowed products to enter warehouses and distribution networks before potentially higher import costs took effect.
This process, known as front-loading, temporarily increases factory output without creating an equivalent increase in final consumption.
That distinction matters enormously for chemical suppliers.
If a pharmaceutical producer manufactures six months of additional inventory in advance, it may need considerably less API, intermediate and process-chemical supply during the following production cycle.
The result can look like a sudden collapse in chemical demand even though patients continue using medicines at broadly normal rates.
Inventory acts as a buffer between manufacturing and consumption.
When inventories are low, pharmaceutical companies must keep production running to meet customer orders. When inventories rise well above normal levels, manufacturers can temporarily reduce production without creating shortages.
That creates a delayed effect.
The production surge happens first. The demand correction arrives later.
For pharmaceutical procurement teams, this means 2025 purchasing data may overstate sustainable demand entering 2026. A supplier that uses last year's exceptional order volumes as its primary forecast could overbuild capacity just as customers begin drawing down existing stocks.
Atradius expects pharmaceutical production growth to slow to 1.6% in 2026, with the retrenchment particularly affecting the first half of the year.
The slowdown does not necessarily indicate weaker pharmaceutical consumption.
It can simply mean manufacturers need time to work through the inventory created during the 2025 front-loading cycle.
This distinction should influence how procurement managers interpret falling purchase orders.
A lower API order does not automatically mean a drug has lost market demand. The customer may simply have sufficient inventory to postpone its next purchase.
The inventory correction can move upstream through the pharmaceutical supply chain.
Finished-drug manufacturers reduce production first. They then purchase fewer APIs and intermediates. API producers subsequently reduce their own requirements for starting materials and process chemicals.
The effect compounds as it moves backward.
A relatively modest reduction in finished-drug production can therefore create a much larger percentage decline in spot purchasing for upstream chemical suppliers.
This makes API and pharmaceutical chemical markets particularly sensitive to inventory cycles.
Traditional market analysis often focuses on end-user consumption.
For pharmaceutical chemicals, that can be misleading during an inventory correction.
A better indicator is the relationship between:
Patient demand → finished-drug inventory → manufacturing schedules → API purchases → chemical input purchases
Each stage responds at a different speed.
A drug may continue selling strongly at pharmacies while the manufacturer temporarily stops purchasing additional API because its warehouse remains full.
Chemical traders that understand this lag can avoid interpreting temporary destocking as permanent market deterioration.
The biggest forecasting mistake would be to annualize 2025's production growth.
A 9.1% production increase creates a much higher comparison base for 2026. If companies then reduce production to normalize inventories, the resulting year-over-year slowdown can appear severe.
That does not necessarily represent a structural collapse.
Procurement managers should therefore separate three variables:
Underlying medicine demand, which reflects actual consumption.
Inventory demand, which reflects stock-building or destocking.
Production demand, which reflects factory scheduling.
The gap between these variables becomes especially important during tariff-driven disruptions.
When inventory reaches a comfortable level, manufacturers can reduce production schedules.
The immediate effects may include:
Lower API purchase volumes.
Longer intervals between purchase orders.
More cautious raw-material procurement.
Reduced spot-market buying.
Greater pressure on supplier pricing.
Delayed capacity expansion.
Higher inventory at upstream suppliers.
For chemical producers, the most difficult stage can be the transition period.
A supplier may have expanded production capacity based on 2025 customer forecasts just as those customers begin reducing orders.
That can create excess capacity and margin pressure.
The relationship between inventory and API pricing can become particularly important.
If pharmaceutical companies temporarily reduce API purchases, suppliers may compete more aggressively for fewer orders.
This can create downward price pressure, especially for APIs with multiple qualified manufacturers and limited differentiation.
Commodity-like pharmaceutical intermediates may experience similar effects.
However, highly specialized APIs with limited production capacity can behave differently. Manufacturers may protect capacity and pricing even when overall production growth slows.
Procurement teams should therefore avoid assuming that every pharmaceutical chemical will follow the same cycle.
Not every medicine experienced the same degree of front-loading.
Products with high US exposure and significant tariff sensitivity had stronger incentives to build inventory.
Other products may have experienced much less stockpiling.
This creates different demand profiles across pharmaceutical categories.
Manufacturers should identify which products generated the largest inventory increases before reducing supplier commitments across their entire portfolio.
A targeted correction is less disruptive than a blanket reduction in procurement.
Pharmaceutical supply chains also differ according to product type.
Innovative medicines can have different production economics, patent positions and inventory strategies from generic products.
Biologics and advanced therapies often require specialized manufacturing processes and supply chains. High-volume small-molecule medicines can have more standardized production and broader supplier bases.
These differences affect how quickly manufacturers can reduce or increase output.
Procurement teams should therefore segment inventory analysis by product rather than applying a single normalization period across the business.
Tariff policy created the incentive for much of the 2025 front-loading cycle.
That means future policy changes can influence whether the inventory correction remains temporary or develops into a longer restructuring of pharmaceutical production.
Companies have responded not only through inventory management but also through US manufacturing investments, pricing agreements and supply-chain diversification. Major drugmakers have accelerated US manufacturing plans as tariff threats intensified.
This creates a second phase of adjustment.
The industry is moving from inventory protection toward structural supply-chain redesign.
Domestic manufacturing investment may prevent the post-front-loading correction from becoming purely negative for equipment and chemical suppliers.
Companies building US plants will need APIs, intermediates and other pharmaceutical manufacturing inputs.
However, new facilities take time to construct, qualify and scale.
That means the demand generated by reshoring may not arrive quickly enough to fully offset the short-term decline created by inventory normalization.
For suppliers, timing matters as much as the eventual size of domestic investment.
International suppliers that benefited from the 2025 production surge may experience a sharp change in customer behavior.
A US customer that previously increased purchases to build inventory could return to normal ordering patterns or temporarily buy below normal levels.
That does not necessarily indicate a loss of supplier competitiveness.
It may simply reflect the customer's inventory position.
Suppliers should therefore distinguish between volume loss caused by destocking and volume loss caused by permanent supplier replacement.
The commercial response should be different in each case.
A falling order book can encourage manufacturers to cut inventory aggressively.
That creates its own risk.
If companies reduce raw-material stocks too far while global supply chains remain exposed to geopolitical disruptions, transportation problems or regulatory changes, they could move from excess inventory to shortage conditions.
The goal should be normalization rather than indiscriminate destocking.
Procurement managers should establish target inventory ranges based on actual lead times and supply risk.
Some APIs and intermediates require long qualification periods.
A manufacturer cannot necessarily reduce purchases today and restore supply next month.
That makes strategic stockholding important even during a demand correction.
Buyers should identify materials where switching suppliers would require:
Regulatory approval.
Process validation.
Stability testing.
New technical documentation.
Manufacturing-scale qualification.
Extended customer audits.
These materials may justify higher safety stocks than less specialized chemicals.
A volatile demand cycle creates opportunities for trading platforms that can connect buyers with multiple qualified suppliers.
When procurement volumes fall, buyers often seek better pricing without sacrificing security of supply.
Traders can support this process by offering alternative origins, flexible quantities and access to suppliers with available capacity.
For buyers, the advantage is greater negotiating flexibility.
For suppliers, diversified customer access can reduce dependence on one pharmaceutical manufacturer whose inventory cycle may temporarily suppress orders.
The post-surge environment may create excess production capacity among some API and chemical manufacturers.
That can improve buyers' negotiating positions.
Procurement teams may find more willingness to discuss:
Longer-term pricing agreements.
Volume flexibility.
Lower minimum order quantities.
Alternative delivery schedules.
Multi-origin supply arrangements.
Capacity reservations.
However, buyers should avoid focusing exclusively on the lowest short-term price.
A supplier that cuts production too aggressively during a downturn may struggle to respond when pharmaceutical demand normalizes.
The most important lesson from the 9.1% surge is that production data can misrepresent underlying demand when companies front-load inventory.
The same problem can occur in reverse.
A sharp production slowdown can exaggerate the appearance of weak pharmaceutical demand when manufacturers are simply working through excess stock.
This distinction is critical for forecasting.
Procurement managers should compare production volumes with inventory levels, shipment data and actual end-market consumption before making major supplier decisions.
A more resilient forecast should use multiple indicators rather than relying on historical purchase volumes.
Teams should monitor:
Inventory days: Determine whether customer inventories remain above normal.
Production schedules: Track factory utilization and planned output.
API orders: Watch both order frequency and volume.
End-market consumption: Separate actual medicine demand from distributor stock movements.
Tariff exposure: Identify products whose production location may change.
Reshoring projects: Track domestic facilities that could eventually shift sourcing patterns.
Supplier capacity: Identify producers with available capacity following the correction.
This approach can distinguish temporary destocking from a genuine structural demand decline.
The pharmaceutical industry may experience very different conditions depending on the product and manufacturing location.
One segment could see weaker orders as companies normalize inventories.
Another could experience new investment as manufacturers build US production capacity and redesign supply chains.
That creates an unusual market environment.
A supplier can face falling orders from an existing overseas facility while simultaneously seeing new demand from a domestic US project.
Procurement teams need to track both trends.
The most important question is what sustainable production looks like after the front-loaded inventory disappears.
If medicine consumption remains healthy, production should eventually return toward underlying demand.
But the geographic distribution of that production may look different.
Some output could move closer to US customers. Some API production could shift to domestic or dual-source facilities. Other products may continue relying on established Asian and European manufacturing networks.
The correction therefore may be less about the pharmaceutical market shrinking and more about the market resetting to a different production footprint.
The 9.1% increase in global pharmaceutical manufacturing output during 2025 should not become the automatic baseline for 2026 planning. Industry analysis attributes the exceptional growth largely to tariff-related front-loading, with Atradius forecasting only 1.6% production growth in 2026 as manufacturers retrench and work through accumulated inventories.
For procurement teams, the coming correction is a reason to improve forecasting rather than simply cut purchasing. API and chemical demand can weaken temporarily even when patient demand remains resilient, making inventory data and production schedules essential complements to traditional sales forecasts.
The opportunity is to use the normalization period to renegotiate supply terms, qualify backup sources and identify which materials deserve strategic inventory protection. As reshoring projects progress, suppliers will also need to distinguish temporary destocking from permanent shifts in manufacturing geography.
For chemical traders, the next phase could be less about chasing exceptional volume and more about helping buyers navigate uneven demand, excess capacity and emerging domestic supply chains.
Featured Product
Found this useful?
Continue Reading
Biosimilars, generic medicines and certain orphan drugs currently sit outside the harshest 2026 Section 232 pharmaceutical tariffs. But a mandated generics review could determine how durable that protection really is.
2026 Gulf shipping disruptions have rippled through global chemical trade routes, delaying Gulf green ammonia/hydrogen project
The global chemical logistics market is projected to reach roughly $317.9 billion in 2026
